The new understanding provided by the RANK/RANKL/OPG paradigm for both differentiation and activation of osteoclasts has ... characterized by excessive bone resorption. Cite this: Osteoprotegerin ...

Adjei, MD Osteoporosis treatment involves the use of effective osteoporosis medications to slow bone loss, increase bone ...

In this target trial emulation study, denosumab was found to increase the risk of hypocalcemia requiring emergency treatment ...

At the recent SEC meeting for analgesics and rheumatology, the expert panel reviewed the proposed Phase I study protocol of ...

"Our findings suggest that Opto-RANK can be used to induce macrophage differentiation into osteoclasts and stimulate local bone resorption when activated by blue light," says Nakata. The precise ...

Osteoprotegerin and its Ligand: A New Paradigm for Regulation of Osteoclastogenesis and Bone Resorption ... with receptors on hematopoietic osteoclast precursor cells. RANK-L: receptor activator ...

This class of drugs slows bone resorption and thereby increases BMD; however, the precise effect of bisphosphonate therapy on the target cell—the osteoclast—remains elusive. As bisphosphonates ...

Researchers from Japan and the US have developed a novel antiresorptive drug, reveromycin A, which inhibits bone resorption by inducing apoptosis in OSTEOCLASTS. In osteoporosis, excessive bone ...